$AGLE Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Aeglea BioTherapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Aeglea BioTherapeutics, Inc.. Get notifications about new insider transactions in Aeglea BioTherapeutics, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 22 2021 | AGLE | Aeglea BioTherapeu ... | Souza Marcio | Director | Option Exercise | A | 6.44 | 60,000 | 386,400 | 60,000 | |
Jun 09 2021 | AGLE | Aeglea BioTherapeu ... | Shanafelt Armen | Director | Option Exercise | A | 6.80 | 40,000 | 272,000 | 40,000 | |
Jun 09 2021 | AGLE | Aeglea BioTherapeu ... | Magovcevic-Liebisch Ivana | Director | Option Exercise | A | 6.80 | 40,000 | 272,000 | 40,000 | |
Feb 25 2021 | AGLE | Aeglea BioTherapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 7.11 | 47,200 | 335,592 | 47,200 | |
Feb 19 2021 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | A | 7.35 | 330,000 | 2,425,500 | 330,000 | |
Feb 19 2021 | AGLE | Aeglea BioTherapeu ... | Hanley Jr. Michael Conick | Chief Commercial Of ... | Option Exercise | A | 7.35 | 135,000 | 992,250 | 135,000 | |
Dec 17 2020 | AGLE | Aeglea BioTherapeu ... | Lawton Alison Frances | Director | Option Exercise | A | 9.09 | 47,200 | 429,048 | 47,200 | |
Jun 10 2020 | AGLE | Aeglea BioTherapeu ... | Shanafelt Armen | Director | Option Exercise | A | 8.89 | 28,100 | 249,809 | 28,100 | |
Jun 10 2020 | AGLE | Aeglea BioTherapeu ... | Mahatme Sandesh | Director | Option Exercise | A | 8.89 | 28,100 | 249,809 | 28,100 | |
Jun 10 2020 | AGLE | Aeglea BioTherapeu ... | Magovcevic Ivana | Director | Option Exercise | A | 8.89 | 28,100 | 249,809 | 28,100 | |
Jun 10 2020 | AGLE | Aeglea BioTherapeu ... | LAWLIS V BRYAN | Director | Option Exercise | A | 8.89 | 28,100 | 249,809 | 28,100 | |
Jun 10 2020 | AGLE | Aeglea BioTherapeu ... | Cox Russell J. | Director | Option Exercise | A | 8.89 | 28,100 | 249,809 | 28,100 | |
Jun 10 2020 | AGLE | Aeglea BioTherapeu ... | Bruhn Suzanne Louise | Director | Option Exercise | A | 8.89 | 28,100 | 249,809 | 28,100 | |
May 04 2020 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 4.75 | 165,000 | 783,750 | 538,469 | 373.5 K to 538.5 K (+44.18 %) |
Feb 19 2020 | AGLE | Aeglea BioTherapeu ... | York Charles N II | Chief Financial Off ... | Option Exercise | A | 8.15 | 126,000 | 1,026,900 | 126,000 | |
Feb 19 2020 | AGLE | Aeglea BioTherapeu ... | Rao Madduri Ravin | Chief Medical Offic ... | Option Exercise | A | 8.15 | 25,000 | 203,750 | 25,000 | |
Feb 19 2020 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | A | 8.15 | 301,000 | 2,453,150 | 301,000 | |
Feb 19 2020 | AGLE | Aeglea BioTherapeu ... | Hanley Jr. Michael Conick | Chief Commercial Of ... | Option Exercise | A | 8.15 | 25,000 | 203,750 | 25,000 | |
Nov 04 2019 | AGLE | Aeglea BioTherapeu ... | Rao Madduri Ravin | Chief Medical Offic ... | Option Exercise | A | 8.24 | 130,000 | 1,071,200 | 130,000 | |
Oct 23 2019 | AGLE | Aeglea BioTherapeu ... | Hanley Jr. Michael Conick | Chief Commercial Of ... | Option Exercise | A | 7.79 | 130,000 | 1,012,700 | 130,000 | |
Oct 07 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | M | 6.31 | 17,603 | 111,075 | 119,914 | |
Oct 07 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | M | 5.46 | 662 | 3,615 | 0 | |
Oct 07 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | M | 6.31 | 17,603 | 111,075 | 371,908 | 354.3 K to 371.9 K (+4.97 %) |
Oct 07 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | M | 5.46 | 662 | 3,615 | 354,305 | 353.6 K to 354.3 K (+0.19 %) |
Jun 14 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.23 | 5,282 | 32,913 | 353,643 | 348.4 K to 353.6 K (+1.52 %) |
Jun 14 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.17 | 14,406 | 88,836 | 348,361 | 334 K to 348.4 K (+4.31 %) |
Jun 14 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.11 | 12,217 | 74,705 | 333,955 | 321.7 K to 334 K (+3.80 %) |
Jun 07 2019 | AGLE | Aeglea BioTherapeu ... | LAWLIS V BRYAN | Director | Option Exercise | A | 6.33 | 12,400 | 78,492 | 12,400 | |
Jun 07 2019 | AGLE | Aeglea BioTherapeu ... | Shanafelt Armen | Director | Option Exercise | A | 6.33 | 12,400 | 78,492 | 12,400 | |
Jun 07 2019 | AGLE | Aeglea BioTherapeu ... | LAWLIS V BRYAN | Director | Option Exercise | A | 6.33 | 12,400 | 78,492 | 12,400 | |
Jun 07 2019 | AGLE | Aeglea BioTherapeu ... | Mahatme Sandesh | Director | Option Exercise | A | 6.33 | 12,400 | 78,492 | 12,400 | |
Jun 07 2019 | AGLE | Aeglea BioTherapeu ... | Magovcevic Ivana | Director | Option Exercise | A | 6.33 | 12,400 | 78,492 | 12,400 | |
Jun 07 2019 | AGLE | Aeglea BioTherapeu ... | Cox Russell J. | Director | Option Exercise | A | 6.33 | 12,400 | 78,492 | 12,400 | |
Jun 07 2019 | AGLE | Aeglea BioTherapeu ... | Shanafelt Armen | Director | Option Exercise | A | 6.33 | 12,400 | 78,492 | 12,400 | |
Jun 07 2019 | AGLE | Aeglea BioTherapeu ... | Bruhn Suzanne Louise | Director | Option Exercise | A | 6.33 | 12,400 | 78,492 | 12,400 | |
Jun 07 2019 | AGLE | Aeglea BioTherapeu ... | Mahatme Sandesh | Director | Option Exercise | A | 6.33 | 12,400 | 78,492 | 12,400 | |
Jun 07 2019 | AGLE | Aeglea BioTherapeu ... | Magovcevic Ivana | Director | Option Exercise | A | 6.33 | 12,400 | 78,492 | 12,400 | |
Jun 07 2019 | AGLE | Aeglea BioTherapeu ... | Cox Russell J. | Director | Option Exercise | A | 6.33 | 12,400 | 78,492 | 12,400 | |
Jun 07 2019 | AGLE | Aeglea BioTherapeu ... | Bruhn Suzanne Louise | Director | Option Exercise | A | 6.33 | 12,400 | 78,492 | 12,400 | |
May 22 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.86 | 3,809 | 26,128 | 321,738 | 317.9 K to 321.7 K (+1.20 %) |
May 22 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.89 | 13,794 | 94,981 | 317,929 | 304.1 K to 317.9 K (+4.54 %) |
May 22 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.56 | 8,989 | 58,923 | 304,135 | 295.1 K to 304.1 K (+3.05 %) |
May 17 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.65 | 6,218 | 41,335 | 295,146 | 288.9 K to 295.1 K (+2.15 %) |
May 17 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.83 | 5,520 | 37,691 | 288,928 | 283.4 K to 288.9 K (+1.95 %) |
May 17 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.76 | 6,256 | 42,269 | 283,408 | 277.2 K to 283.4 K (+2.26 %) |
May 17 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 7.10 | 719 | 5,103 | 277,152 | 276.4 K to 277.2 K (+0.26 %) |
Mar 08 2019 | AGLE | Aeglea BioTherapeu ... | Sloan Leslie | Chief Operating Off ... | Option Exercise | A | 8.06 | 36,000 | 290,160 | 36,000 | |
Feb 08 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | M | 6.31 | 7,433 | 46,902 | 137,517 | |
Feb 08 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | M | 5.46 | 1,323 | 7,224 | 662 | |
Feb 08 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | M | 6.31 | 7,433 | 46,902 | 276,433 | 269 K to 276.4 K (+2.76 %) |
Feb 08 2019 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | M | 5.46 | 1,323 | 7,224 | 269,000 | 267.7 K to 269 K (+0.49 %) |
Dec 10 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | M | 6.31 | 18,584 | 117,265 | 144,950 | |
Dec 10 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | M | 5.46 | 3,306 | 18,051 | 1,985 | |
Dec 10 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | M | 4.11 | 150,000 | 616,500 | 0 | |
Dec 10 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | M | 6.31 | 18,584 | 117,265 | 267,677 | 249.1 K to 267.7 K (+7.46 %) |
Dec 10 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | M | 5.46 | 3,306 | 18,051 | 249,093 | 245.8 K to 249.1 K (+1.35 %) |
Dec 10 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | M | 4.11 | 150,000 | 616,500 | 245,787 | 95.8 K to 245.8 K (+156.60 %) |
Dec 10 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 9.13 | 994 | 9,075 | 95,787 | 94.8 K to 95.8 K (+1.05 %) |
Dec 10 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Buy | P | 6.02 | 2,000 | 12,040 | 94,793 | 92.8 K to 94.8 K (+2.16 %) |
Sep 28 2018 | AGLE | Aeglea BioTherapeu ... | Schuchart Aaron | Chief Business Offi ... | Sell | S | 9.50 | 5,900 | 56,050 | 2,500 | 8.4 K to 2.5 K (-70.24 %) |
Sep 28 2018 | AGLE | Aeglea BioTherapeu ... | Schuchart Aaron | Chief Business Offi ... | Sell | S | 9.55 | 100 | 955 | 8,400 | 8.5 K to 8.4 K (-1.18 %) |
Aug 21 2018 | AGLE | Aeglea BioTherapeu ... | Schuchart Aaron | Chief Business Offi ... | Option Exercise | M | 3.50 | 8,500 | 29,750 | 91,500 | |
Aug 21 2018 | AGLE | Aeglea BioTherapeu ... | Schuchart Aaron | Chief Business Offi ... | Buy | M | 3.50 | 8,500 | 29,750 | 8,500 | 0 to 8.5 K |
Aug 15 2018 | AGLE | Aeglea BioTherapeu ... | GEORGIOU GEORGE | Director | Option Exercise | M | 4.73 | 20,000 | 94,600 | 10,000 | |
Aug 15 2018 | AGLE | Aeglea BioTherapeu ... | GEORGIOU GEORGE | Director | Option Exercise | M | 7.28 | 17,333 | 126,184 | 6,667 | |
Aug 15 2018 | AGLE | Aeglea BioTherapeu ... | GEORGIOU GEORGE | Director | Buy | M | 4.73 | 20,000 | 94,600 | 175,861 | 155.9 K to 175.9 K (+12.83 %) |
Aug 15 2018 | AGLE | Aeglea BioTherapeu ... | GEORGIOU GEORGE | Director | Buy | M | 7.28 | 17,333 | 126,184 | 155,861 | 138.5 K to 155.9 K (+12.51 %) |
Jul 20 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | A | 9.36 | 50,000 | 468,000 | 50,000 | |
Jul 20 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | A | 9.36 | 75,000 | 702,000 | 75,000 | |
Jul 20 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | A | 9.36 | 75,000 | 702,000 | 75,000 | |
Jul 20 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | President & CEO | Option Exercise | A | 9.36 | 300,000 | 2,808,000 | 300,000 | |
Jul 17 2018 | AGLE | Aeglea BioTherapeu ... | LAWLIS V BRYAN | Director | Option Exercise | A | 8.78 | 36,800 | 323,104 | 36,800 | |
Jul 16 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Option Exercise | M | 6.31 | 14,866 | 93,804 | 163,534 | |
Jul 16 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Option Exercise | M | 7.04 | 24,000 | 168,960 | 0 | |
Jul 16 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Buy | M | 6.31 | 14,866 | 93,804 | 92,793 | 77.9 K to 92.8 K (+19.08 %) |
Jul 16 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Buy | M | 7.04 | 24,000 | 168,960 | 77,927 | 53.9 K to 77.9 K (+44.50 %) |
Jul 13 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Option Exercise | M | 5.46 | 3,307 | 18,056 | 5,291 | |
Jul 13 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Buy | M | 5.46 | 3,307 | 18,056 | 53,927 | 50.6 K to 53.9 K (+6.53 %) |
Jun 08 2018 | AGLE | Aeglea BioTherapeu ... | Shanafelt Armen | Director | Option Exercise | A | 10.28 | 18,400 | 189,152 | 18,400 | |
Jun 08 2018 | AGLE | Aeglea BioTherapeu ... | Mahatme Sandesh | Director | Option Exercise | A | 10.28 | 18,400 | 189,152 | 18,400 | |
Jun 08 2018 | AGLE | Aeglea BioTherapeu ... | GEORGIOU GEORGE | Director | Option Exercise | A | 10.28 | 18,400 | 189,152 | 18,400 | |
Jun 08 2018 | AGLE | Aeglea BioTherapeu ... | Cox Russell J. | Director | Option Exercise | A | 10.28 | 18,400 | 189,152 | 18,400 | |
Jun 08 2018 | AGLE | Aeglea BioTherapeu ... | Bruhn Suzanne Louise | Director | Option Exercise | A | 10.28 | 18,400 | 189,152 | 18,400 | |
May 14 2018 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | Sell | S | 10.06 | 19,550 | 196,673 | 2,175,314 | 2.2 M to 2.2 M (-0.89 %) | |
May 11 2018 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | Sell | S | 10.13 | 22,725 | 230,204 | 2,194,864 | 2.2 M to 2.2 M (-1.02 %) | |
May 11 2018 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | Sell | S | 10.11 | 51,230 | 517,935 | 2,217,589 | 2.3 M to 2.2 M (-2.26 %) | |
May 09 2018 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | Sell | S | 10.03 | 26,557 | 266,367 | 2,268,819 | 2.3 M to 2.3 M (-1.16 %) | |
May 09 2018 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | Sell | S | 10.11 | 15,548 | 157,190 | 2,295,376 | 2.3 M to 2.3 M (-0.67 %) | |
Mar 26 2018 | AGLE | Aeglea BioTherapeu ... | Magovcevic Ivana | Director | Option Exercise | A | 10.50 | 36,800 | 386,400 | 36,800 | |
Feb 22 2018 | AGLE | Aeglea BioTherapeu ... | Wooldridge James | Chief Medical Offic ... | Option Exercise | A | 6.31 | 45,000 | 283,950 | 45,000 | |
Feb 22 2018 | AGLE | Aeglea BioTherapeu ... | York Charles N II | Chief Financial Off ... | Option Exercise | A | 6.31 | 92,100 | 581,151 | 92,100 | |
Feb 22 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Option Exercise | A | 6.31 | 178,400 | 1,125,704 | 178,400 | |
Feb 22 2018 | AGLE | Aeglea BioTherapeu ... | Schuchart Aaron | Chief Business Offi ... | Option Exercise | A | 6.31 | 20,000 | 126,200 | 20,000 | |
Feb 20 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Option Exercise | M | 5.46 | 15,211 | 83,052 | 8,598 | |
Feb 20 2018 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Buy | M | 5.46 | 15,211 | 83,052 | 50,620 | 35.4 K to 50.6 K (+42.96 %) |
Dec 08 2017 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Buy | P | 5.07 | 600 | 3,039 | 35,409 | 34.8 K to 35.4 K (+1.72 %) |
Dec 08 2017 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Buy | P | 4.99 | 2,800 | 13,967 | 34,809 | 32 K to 34.8 K (+8.75 %) |
Dec 08 2017 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Buy | P | 4.92 | 4,888 | 24,072 | 32,009 | 27.1 K to 32 K (+18.02 %) |
Dec 05 2017 | AGLE | Aeglea BioTherapeu ... | York Charles N II | Chief Financial Off ... | Buy | P | 4.76 | 10,241 | 48,700 | 34,787 | 24.5 K to 34.8 K (+41.72 %) |
Dec 05 2017 | AGLE | Aeglea BioTherapeu ... | York Charles N II | Chief Financial Off ... | Buy | P | 4.97 | 3,259 | 16,197 | 24,546 | 21.3 K to 24.5 K (+15.31 %) |
Dec 05 2017 | AGLE | Aeglea BioTherapeu ... | York Charles N II | Chief Financial Off ... | Buy | P | 4.59 | 6,500 | 29,855 | 21,287 | 14.8 K to 21.3 K (+43.96 %) |
Dec 05 2017 | AGLE | Aeglea BioTherapeu ... | York Charles N II | Chief Financial Off ... | Buy | P | 2.52 | 1,959 | 4,929 | 14,787 | 12.8 K to 14.8 K (+15.27 %) |
Dec 05 2017 | AGLE | Aeglea BioTherapeu ... | York Charles N II | Chief Financial Off ... | Buy | P | 4.28 | 2,000 | 8,568 | 12,828 | 10.8 K to 12.8 K (+18.47 %) |
Dec 05 2017 | AGLE | Aeglea BioTherapeu ... | York Charles N II | Chief Financial Off ... | Buy | P | 3.99 | 2,000 | 7,974 | 10,828 | 8.8 K to 10.8 K (+22.66 %) |
Dec 05 2017 | AGLE | Aeglea BioTherapeu ... | Shanafelt Armen | Director | Option Exercise | A | 4.73 | 30,000 | 141,900 | 30,000 | |
Dec 05 2017 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Director | Buy | P | 4.93 | 5,065 | 24,976 | 27,121 | 22.1 K to 27.1 K (+22.96 %) |
Dec 05 2017 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Director | Buy | P | 4.98 | 7,956 | 39,624 | 22,056 | 14.1 K to 22.1 K (+56.43 %) |
Dec 05 2017 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Director | Buy | P | 4.53 | 4,100 | 18,578 | 14,100 | 10 K to 14.1 K (+41.00 %) |
Dec 05 2017 | AGLE | Aeglea BioTherapeu ... | Mahatme Sandesh | Director | Option Exercise | A | 4.73 | 30,000 | 141,900 | 30,000 | |
Dec 05 2017 | AGLE | Aeglea BioTherapeu ... | GEORGIOU GEORGE | Director | Option Exercise | A | 4.73 | 30,000 | 141,900 | 30,000 | |
Dec 05 2017 | AGLE | Aeglea BioTherapeu ... | Cox Russell J. | Director | Option Exercise | A | 4.73 | 30,000 | 141,900 | 30,000 | |
Sep 01 2017 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony G. | Interim CEO | Option Exercise | A | 4.11 | 150,000 | 616,500 | 150,000 | |
Aug 24 2017 | AGLE | Aeglea BioTherapeu ... | York Charles N II | Chief Financial Off ... | Option Exercise | A | 3.10 | 58,500 | 181,350 | 58,500 | |
Aug 24 2017 | AGLE | Aeglea BioTherapeu ... | Wooldridge James | Chief Medical Offic ... | Option Exercise | A | 3.10 | 10,000 | 31,000 | 10,000 | |
Aug 24 2017 | AGLE | Aeglea BioTherapeu ... | Wooldridge James | Chief Medical Offic ... | Option Exercise | A | 3.10 | 165,000 | 511,500 | 165,000 | |
Aug 24 2017 | AGLE | Aeglea BioTherapeu ... | TYLER JOSEPH E | VP, Manufacturing | Option Exercise | A | 3.10 | 25,000 | 77,500 | 25,000 | |
Aug 24 2017 | AGLE | Aeglea BioTherapeu ... | Schuchart Aaron | Chief Business Offi ... | Option Exercise | A | 3.10 | 10,000 | 31,000 | 10,000 | |
Aug 24 2017 | AGLE | Aeglea BioTherapeu ... | Rowlinson Scott W | VP, Research | Option Exercise | A | 3.10 | 25,000 | 77,500 | 25,000 | |
Jun 20 2017 | AGLE | Aeglea BioTherapeu ... | Schuchart Aaron | Chief Business Offi ... | Option Exercise | A | 3.50 | 100,000 | 350,000 | 100,000 | |
Apr 25 2017 | AGLE | Aeglea BioTherapeu ... | Quinn Anthony | interim Chief Medic ... | Option Exercise | A | 7.04 | 24,000 | 168,960 | 24,000 | |
Mar 22 2017 | AGLE | Aeglea BioTherapeu ... | York Charles N II | Chief Financial Off ... | Option Exercise | A | 8.03 | 90,000 | 722,700 | 90,000 | |
Mar 22 2017 | AGLE | Aeglea BioTherapeu ... | TYLER JOSEPH E | VP, Manufacturing | Option Exercise | A | 8.03 | 39,000 | 313,170 | 39,000 | |
Mar 22 2017 | AGLE | Aeglea BioTherapeu ... | Rowlinson Scott W | VP, Research | Option Exercise | A | 8.03 | 60,000 | 481,800 | 60,000 | |
Mar 22 2017 | AGLE | Aeglea BioTherapeu ... | Lowe David George | CEO and President | Option Exercise | A | 8.03 | 160,000 | 1,284,800 | 160,000 | |
Mar 22 2017 | AGLE | Aeglea BioTherapeu ... | Hebel Henry | VP, Product Develop ... | Option Exercise | A | 8.03 | 38,200 | 306,746 | 38,200 | |
Feb 21 2017 | AGLE | Aeglea BioTherapeu ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 5.36 | 7,000 | 37,520 | 1,469,524 | 1.5 M to 1.5 M (+0.48 %) |
Feb 21 2017 | AGLE | Aeglea BioTherapeu ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 5.19 | 71,800 | 372,642 | 1,462,524 | 1.4 M to 1.5 M (+5.16 %) |
Feb 21 2017 | AGLE | Aeglea BioTherapeu ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 5.04 | 30,500 | 153,720 | 1,390,724 | 1.4 M to 1.4 M (+2.24 %) |
Feb 16 2017 | AGLE | Aeglea BioTherapeu ... | Bruhn Suzanne Louise | Director | Option Exercise | A | 5.04 | 82,000 | 413,280 | 82,000 | |
May 19 2016 | AGLE | Aeglea BioTherapeu ... | York Charles N II | Chief Financial Off ... | Option Exercise | A | 7.28 | 55,000 | 400,400 | 55,000 | |
May 19 2016 | AGLE | Aeglea BioTherapeu ... | TYLER JOSEPH E | VP, Manufacturing | Option Exercise | A | 7.28 | 33,000 | 240,240 | 33,000 | |
May 19 2016 | AGLE | Aeglea BioTherapeu ... | Shanafelt Armen | Director | Option Exercise | A | 7.28 | 24,000 | 174,720 | 24,000 | |
May 19 2016 | AGLE | Aeglea BioTherapeu ... | Rowlinson Scott W | VP, Research | Option Exercise | A | 7.28 | 47,000 | 342,160 | 47,000 | |
May 19 2016 | AGLE | Aeglea BioTherapeu ... | Rojas-Caro Sandra | Chief Medical Offic ... | Option Exercise | A | 7.28 | 200,000 | 1,456,000 | 200,000 | |
May 19 2016 | AGLE | Aeglea BioTherapeu ... | Mahatme Sandesh | Director | Option Exercise | A | 7.28 | 10,000 | 72,800 | 10,000 | |
May 19 2016 | AGLE | Aeglea BioTherapeu ... | Lowe David George | CEO and President | Option Exercise | A | 7.28 | 160,000 | 1,164,800 | 160,000 | |
May 19 2016 | AGLE | Aeglea BioTherapeu ... | Hebel Henry | VP, Product Develop ... | Option Exercise | A | 7.28 | 43,000 | 313,040 | 43,000 | |
May 19 2016 | AGLE | Aeglea BioTherapeu ... | GEORGIOU GEORGE | Director | Option Exercise | A | 7.28 | 24,000 | 174,720 | 24,000 | |
May 19 2016 | AGLE | Aeglea BioTherapeu ... | Cox Russell J. | Director | Option Exercise | A | 7.28 | 10,000 | 72,800 | 10,000 | |
Apr 14 2016 | AGLE | Aeglea BioTherapeu ... | LILLY ELI & CO | 10% Owner | Option Exercise | C | 0.00 | 1,120,448 | 0 | 0 | |
Apr 14 2016 | AGLE | Aeglea BioTherapeu ... | LILLY ELI & CO | 10% Owner | Option Exercise | C | 0.00 | 890,476 | 0 | 0 | |
Apr 14 2016 | AGLE | Aeglea BioTherapeu ... | LILLY ELI & CO | 10% Owner | Buy | P | 10.00 | 500,000 | 5,000,000 | 2,568,543 | 2.1 M to 2.6 M (+24.17 %) |
Apr 14 2016 | AGLE | Aeglea BioTherapeu ... | LILLY ELI & CO | 10% Owner | Buy | C | 0.00 | 2,010,924 | 0 | 2,068,543 | 57.6 K to 2.1 M (+3,490.04 %) |
Apr 12 2016 | AGLE | Aeglea BioTherapeu ... | York Charles N II | Chief Financial Off ... | Option Exercise | C | 0.00 | 2,037 | 0 | 0 | |
Apr 12 2016 | AGLE | Aeglea BioTherapeu ... | York Charles N II | Chief Financial Off ... | Option Exercise | C | 0.00 | 9,523 | 0 | 0 | |
Apr 12 2016 | AGLE | Aeglea BioTherapeu ... | York Charles N II | Chief Financial Off ... | Option Exercise | C | 0.00 | 1,324 | 0 | 0 | |
Apr 12 2016 | AGLE | Aeglea BioTherapeu ... | York Charles N II | Chief Financial Off ... | Buy | C | 0.00 | 11,560 | 0 | 11,560 | 0 to 11.6 K |
Apr 12 2016 | AGLE | Aeglea BioTherapeu ... | York Charles N II | Chief Financial Off ... | Buy | C | 0.00 | 1,324 | 0 | 8,828 | 7.5 K to 8.8 K (+17.64 %) |
Apr 12 2016 | AGLE | Aeglea BioTherapeu ... | TYLER JOSEPH E | VP, Manufacturing | Option Exercise | C | 0.00 | 8,403 | 0 | 0 | |
Apr 12 2016 | AGLE | Aeglea BioTherapeu ... | TYLER JOSEPH E | VP, Manufacturing | Option Exercise | C | 0.00 | 22,857 | 0 | 0 |